Where is GigaGen located?

GigaGen is headquartered in San Francisco, United States. It is registered at South San Francisco, California.

How many employees does GigaGen have?

As of Sep 30, 2026, the latest employee count at GigaGen is 56.

Is GigaGen a funded company?

GigaGen is a funded company, having raised a total of $36.1M across 19 funding rounds to date. The company's 1st funding round was a $***** Seed round.

How much is GigaGen worth?

The last known valuation of GigaGen was $***** as of Mar 09, 2021.

When was the latest funding round of GigaGen?

GigaGen's latest funding was a $***** Grant (prize money) round on Jan 16, 2018, with participation from 1 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $4.78B in funding in 2026 to date.

Where does GigaGen rank among its competitors?

GigaGen ranks 17th amongst 444 active competitors, of which 163 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of GigaGen?

GigaGen's top competitors include Agios Pharmaceuticals, Sana Biotechnology and Abcellera Biologics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

GigaGen - 2026 Company Profile, Team, Funding & Competitors

Q: Is GigaGen an acquired company?

GigaGen got acquired by Grifols on Mar 09, 2021.

Company Details

GigaGen is a developer of T-cell and antibody-based therapeutics. Its high-throughput single-cell sequencing and protein expression platform use microfluidics, bioinformatics, next-generation sequencing, and genetic engineering for full length natively paired antibodies and T cell receptors (TCRs). It claims that its platform integrates cell clonal identity, function, and target binding across several single primary B or T cells.

Website: www.gigagen.com/
Social
Registered Address: South San Francisco, California

Key Metrics

Founded Year

2011

Location

San Francisco, United States

Stage

Acquired

Total Funding

$36.1M in 19 rounds

Latest Funding Round

Grant (prize money), Jan 16, 2018, $*****

Last Known Valuation

$***** as on Mar 09, 2021

Investors

Claremont Creek Ventures & 6 more

Ranked

17^th among 444 active competitors

Employee Count

56 as on Sep 30, 2026

Similar Companies

Agios Pharmaceuticals & 552 more

Exit Details

Acquired by Grifols (Mar 09, 2021)

View GigaGen's full profile

GigaGen is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Gigagen Inc. CIN: 272491233 , United States, Active	Dec 26, 999	-	36 (As on Dec 31, 2022)	-

GigaGen got acquired by Grifols on Mar 09, 2021 at an acquisition amount of $*****.

Click here to take a look at GigaGen's acquisition in detail

GigaGen has raised a total funding of $36.1M over 19 rounds. Its latest funding round was a Grant (prize money) round on Jan 16, 2018 for $*****. 1 investor participated in its latest round. GigaGen has 7 institutional investors.

Here is the list of recent funding rounds of GigaGen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 16, 2018	6387609	Grant (prize money)	1488808	2872641	1065984	7227884
Jul 18, 2017	2306382	Series B	9447198	1979261	2896906	7539692
Jul 01, 2016	5691383	Grant (prize money)	9966216	9328291	7061326	HHS

Access funding benchmarks and valuations. Sign up today!

View details of GigaGen's funding rounds and investors

The founders of GigaGen is Everett Meyer.

Here are the details of GigaGen's key team members:

Everett Meyer: Co-Founder of GigaGen.

View details of GigaGen's Founder profiles and Board Members

GigaGen's employee count trend

GigaGen has 56 employees as of Sep 26. Here is GigaGen's employee count trend over the years:

Uncover GigaGen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GigaGen include Agios Pharmaceuticals, Sana Biotechnology and Abcellera Biologics. Here is the list of Top 10 competitors of GigaGen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	72/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	69/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	68/100
4th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	67/100
5th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 8 others	64/100
6th	Cue Biopharma 2015, Cambridge (United States), Public	Precision immunotherapies to transform patients' lives by selectively modulating the immune system	$26.4M	MDB Capital	64/100
7th	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Symbiosis, Credit Mutuel Equity & 11 others	63/100
8th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	62/100
9th	Janux Therapeutics 2017, San Diego (United States), Public	Developer of immunotherapeutics for the treatment of cancer	$181M	RA Capital Management, Avalon Ventures & 10 others	62/100
10th	FoRx Therapeutics 2019, Basel (Switzerland), Series A	Developer of compounds for treating cancer	$60.8M	Omega Funds, Novartis Venture Fund & 5 others	62/100
17th	GigaGen 2011, San Francisco (United States), Acquired	Developer of T-cell and antibody-based therapeutics	$36.1M	Claremont Creek Ventures, DOE & 5 others	59/100